Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Nature

• Publication date

  1992-03-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/356215A0PMID 1552940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.

  1991cited by this paper
• Tumor suppressor genes.

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

  1990cited by this paper
• p53 functions as a cell cycle control protein in osteosarcomas

  1990cited by this paper
• Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

  1990cited by this paper
• Suppression of human colorectal carcinoma cell growth by wild-type p53.

  1990cited by this paper
• Structural aspects of the p53 protein in relation to gene evolution.

  1990cited by this paper
• A deadly inheritance

  1990cited by this paper
• Genetic mechanisms of tumor suppression by the human p53 gene

  1990cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• Cancer. A deadly inheritance.

  1990cited by this paper
• Presence of a potent transcription activating sequence in the p53 protein.

  1990cited by this paper
• Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

  1990cited by this paper
• p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.

  1990cited by this paper
• Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.

  1990cited by this paper
• Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.

  1990cited by this paper
• Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.

  1990cited by this paper
• Association of human papillomavirus types 16 and 18 E6 proteins with p53.

  1990cited by this paper
• Wild-type p53 can inhibit oncogene-mediated focus formation.

  1989cited by this paper
• Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human alpha-1-antitrypsin gene.

  1989cited by this paper
• The p53 proto-oncogene can act as a suppressor of transformation.

  1989cited by this paper
• High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

  1989cited by this paper
• Mortality, Major Cause of Moribundity, and Spontaneous Tumors in CD-1 Mice

  1988cited by this paper
• Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes

  1988cited by this paper
• Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus.

  1988cited by this paper
• p53 and DNA polymerase α compete for binding to SV40 T antigen

  1987cited by this paper
• Ovarian Choriocarcinoma in the Mouse

  1987cited by this paper
• Mouse p53 inhibits SV40 origin-dependent DNA replication

  1987cited by this paper
• p53 and DNA polymerase alpha compete for binding to SV40 T antigen.

  1987cited by this paper
• Monoclonal antibody analysis of p53 expression in normal and transformed cells

  1986cited by this paper
• The cellular oncogene p53 can be activated by mutagenesis

  1985cited by this paper
• Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products

  1985cited by this paper
• p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors

  1985cited by this paper
• Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

  1984cited by this paper
• Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences

  1984cited by this paper
• Structural comparisons of wild-type and nuclear transport-defective simian virus 40 large tumor antigens.

  1984cited by this paper
• Analysis of the gene coding for the murine cellular tumour antigen p53.

  1984cited by this paper
• Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

  1984cited by this paper
• Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53

  1984cited by this paper
• Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.

  1982cited by this paper
• Monoclonal antibodies specific for simian virus 40 tumor antigens

  1981cited by this paper
• A monoclonal antibody that recognizes B cells and B cell precursors in mice

  1981cited by this paper
• p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells.

  1981cited by this paper
• Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

  1979cited by this paper
• T antigen is bound to a host protein in SY40-transformed cells

  1979cited by this paper
• Pathology of Laboratory Animals

  1978cited by this paper
• Cell-mediated immunity and aging.

  1974cited by this paper
• A new inbred subline of mice (129-terSv) with a high incidence of spontaneous congenital testicular teratomas.

  1973cited by this paper

• E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model

  2026cites this paper
• The TP53 gene contains a diversity box that makes it more than a tumor suppressor.

  2026cites this paper
• Senescence-inhibitory Δ133p53α counteracts accelerated ageing and mortality

  2026cites this paper
• The application of experimental models for the drug discovery for digestive tumors.

  2026cites this paper
• TP53 Deficiency in the Natural History of Prostate Cancer

  2025cites this paper
• Li-Fraumeni Syndrome-Associated p53 Variants Disrupt Kidney and Urinary Tract Development

  2025cites this paper
• Mutant p53: evolving perspectives

  2025cites this paper
• Development of CRISRP/Cas9-based TP53-knockout pig muscle stem cells for use in the cultured meat industry

  2025cites this paper
• Hesperidin protects against sodium fluoride-induced molecular, stereological, and behavioral alterations in the rat cerebellum.

  2025cites this paper
• Ergothioneine Stimulates Ca2+-Mediated Brain-Derived Neurotrophic Factor Expression in NE-4C Nerve Cells

  2025cites this paper
• Distinct functional heterogeneity of TP53 R175 mutations in platinum-resistant ovarian cancer: unveiling molecular mechanisms and therapeutic targets

  2025cites this paper
• Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

  2025cites this paper
• MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.

  2025cites this paper
• Dissecting cross‐lineage tumourigenesis under p53 inactivation through single‐cell multi‐omics and spatial transcriptomics

  2025cites this paper
• HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan

  2025cites this paper
• The relationship between copper metabolism and p53 activity in tumors.

  2025cites this paper
• p53-induced RNA-binding protein ZMAT3 inhibits transcription of a hexokinase to suppress mitochondrial respiration

  2025cites this paper
• Oncogenic and teratogenic effects of Trp53Y217C, an inflammation-prone mouse model of the human hotspot mutant TP53Y220C

  2025cites this paper
• The Expressions of Noc2l (NOC2-Like Nucleolar Associated Transcriptional Repressor) and p53 in the Mouse Uterus Through the Peri-Implantation Duration

  2025cites this paper
• Phase Separation and Prion‐Like Aggregation of p53 Family Tumor Suppressors: From Protein Evolution to Cancer Treatment

  2025cites this paper
• Harnessing p53 for targeted cancer therapy: new advances and future directions

  2025cites this paper
• Mice carrying nonsense mutant p53 develop frequent multicentric or metastatic tumors

  2025cites this paper
• Identification of Ageing-related Hub Genes in Humans, Mouse and Rat Based on Bioinformatics Analysis.

  2025cites this paper
• The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations

  2025cites this paper
• Preclinical models of soft tissue sarcomas - generation and applications to enhance translational research.

  2025cites this paper
• Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations

  2025cites this paper
• Alternative Splicing: Emerging Roles in Anti-Aging Strategies

  2025cites this paper
• Mis-splicing drives loss of function of p53E224D point mutation

  2025cites this paper
• Hepatoblastoma Cell Lines: Past, Present and Future

  2025cites this paper
• Mouse ZGRF1 helicase facilitates DNA repair and maintains efficient fertility

  2025cites this paper
• Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells

  2025cites this paper
• Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.

  2025cites this paper
• Hippo Signaling Is Essential for the Maintenance of Zona Glomerulosa Cell Fate in the Murine Adrenal Cortex

  2025cites this paper
• Transcriptional profiling reveals upregulation of p53 signaling in porcine embryos produced in vitro

  2025cites this paper
• The TP53 tumor suppressor gene: From molecular biology to clinical investigations

  2025cites this paper
• The senescence-inhibitory p53 isoform Δ133p53α: enhancing cancer immunotherapy and exploring novel therapeutic approaches for senescence-associated diseases.

  2025cites this paper
• p53 mutation-associated prognosis across cancer types underlines hematological malignancy as an applicable cancer type to p53-rescue therapy

  2025cites this paper
• Pharmacologic activation of Δ133p53α reduces cellular senescence in progeria patients-derived cells.

  2025cites this paper
• Germline TP53 p.R337H and XAF1 p.E134* Variants: Prevalence in Paraguay and Comparison with Rates in Brazilian State of Paraná and Previous Findings at the Paraguayan–Brazilian Border

  2025cites this paper
• Δ133p53α-mediated inhibition of astrocyte senescence and neurotoxicity as a possible therapeutic approach for neurodegenerative diseases.

  2025cites this paper
• Facing the Challenge to Mimic Breast Cancer Heterogeneity: Established and Emerging Experimental Preclinical Models Integrated with Omics Technologies

  2025cites this paper
• p21, ccng1, foxo3b, and fbxw7 contribute to p53-dependent cell cycle arrest

  2025cites this paper
• Pharmacologic activation of Δ133p53α reduces cellular senescence in progeria patients-derived cells

  2025cites this paper
• Activation of T cell-intrinsic p53 by acetylation elicits antitumor immunity to boost cancer immunotherapy.

  2025cites this paper
• Multihit Somatic Mosaicism of TP53 Pathogenic Variants in a Patient Mimicking Li-Fraumeni Syndrome.

  2025cites this paper
• Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses

  2025cites this paper
• In vivo cancer modeling using mouse models.

  2025cites this paper
• Reduction in vinculin levels with Rb1 loss is responsible for altered differentiation in preosteoblasts.

  2025cites this paper
• Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss-No Target Is Out of the Realm of Possibility.

  2025cites this paper
• A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins

  2025cites this paper
• A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment

  2024cites this paper
• Engineered extrachromosomal oncogene amplifications promote tumorigenesis

  2024cites this paper
• Targeting senescent cells for the treatment of age-associated diseases.

  2024cites this paper
• Eine neue Funktion für HIF: die Umstellung des Metabolismus im Zellzyklus

  2024cites this paper
• Breathing new insights into the role of mutant p53 in lung cancer

  2024cites this paper
• Human stem cell models to unravel brain cancer

  2024cites this paper
• Myeloid Mir34a suppresses colitis-associated colon cancer: characterization of mediators by single-cell RNA sequencing

  2024cites this paper
• DNA damage–induced p53 downregulates expression of RAG1 through a negative feedback loop involving miR-34a and FOXP1

  2024cites this paper
• Telomere function and regulation from mouse models to human ageing and disease

  2024cites this paper
• Cellular senescence: mechanisms and relevance to cancer and aging

  2024cites this paper
• Rodent models of tumours of the central nervous system

  2024cites this paper
• Wnt/B-catenin activation and TP53 mutations associate with distinct immune profiles in advanced thyroid cancer.

  2024cites this paper
• Genetic Screen in a Pre-Clinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities.

  2024cites this paper
• Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease

  2024cites this paper
• Mastering Death: The Roles of Viral Bcl-2 in dsDNA Viruses

  2024cites this paper
• The Evolution of Mouse Models of Cancer: Past, Present, and Future.

  2024cites this paper
• The potential role of circular RNAs in regulating p53 in different types of cancers.

  2024cites this paper
• Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines

  2024cites this paper
• p53 inhibitor or antioxidants reduce the severity of ethmoid plate deformities in zebrafish Type 3 Treacher Collins syndrome model.

  2024cites this paper
• The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

  2024cites this paper
• Mouse models to investigate in situ cell fate decisions induced by p53

  2024cites this paper
• Don't fear the reaper: The role of regulated cell death in tumorigenesis and BH3-mimetics for cancer therapy.

  2024cites this paper
• Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?

  2024cites this paper
• Current development of theragnostic nanoparticles for women’s cancer treatment

  2024cites this paper
• Methods to study xenografted human cancer in genetically diverse mice

  2024cites this paper
• SIRT7 and p53 interaction in embryonic development and tumorigenesis

  2024cites this paper
• Translating p53-based therapies for cancer into the clinic

  2024cites this paper
• The p53 protein - not only the guardian of the genome.

  2024cites this paper
• Putative Molecular Mechanisms Underpinning the Inverse Roles of Mitochondrial Respiration and Heme Function in Lung Cancer and Alzheimer’s Disease

  2024cites this paper
• TCTP regulates genotoxic stress and tumorigenicity via intercellular vesicular signaling

  2024cites this paper
• Genetic Signature of Human Pancreatic Cancer and Personalized Targeting

  2024cites this paper
• Evaluating targeted therapies in older patients with TP53-mutated AML

  2024cites this paper
• Considerations for cultivated crustacean meat: potential cell sources, potential differentiation and immortalization strategies, and lessons from crustacean and other animal models

  2024cites this paper
• p53/MDM2 signaling pathway in aging, senescence and tumorigenesis.

  2024cites this paper
• SATB1, senescence and senescence‐related diseases

  2024cites this paper
• How MicroRNAs Command the Battle against Cancer

  2024cites this paper
• Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms

  2024cites this paper
• p53 regulates diverse tissue-specific outcomes to endogenous DNA damage in mice

  2024cites this paper
• An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.

  2024cites this paper
• PTEN as an apologist of chromosomes from the aggressor cancer: mechanisms of chromosomal instability and prevention of aneuploidy

  2024cites this paper
• RNF4 sustains Myc-driven tumorigenesis by facilitating DNA replication

  2024cites this paper
• A p53/LINC00324 positive feedback loop suppresses tumor growth by counteracting SET-mediated transcriptional repression.

  2023cites this paper
• Characterization of a rhabdomyosarcoma reveals a critical role for SMG7 in cancer cell viability and tumor growth

  2023cites this paper
• How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research.

  2023cites this paper
• Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis.

  2023cites this paper
• Genotoxic aldehyde stress prematurely ages hematopoietic stem cells in a p53-driven manner

  2023cites this paper
• Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis

  2023cites this paper
• Advances in Making Cancer Mouse Models More Accessible and Informative through Non-Germline Genetic Engineering.

  2023cites this paper
• Mouse models in colon cancer, inferences, and implications

  2023cites this paper
• BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature.

  2023cites this paper